Athersys, Inc. (ATHX) Given a $12.00 Price Target by Maxim Group Analysts

Athersys, Inc. (NASDAQ:ATHX) has been given a $12.00 price target by analysts at Maxim Group in a report issued on Monday, August 7th, Marketbeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock.

Shares of Athersys (ATHX) traded up 1.21% during midday trading on Monday, hitting $1.67. The company had a trading volume of 379,106 shares. Athersys has a 12 month low of $1.02 and a 12 month high of $2.30. The company has a 50-day moving average of $1.60 and a 200 day moving average of $1.43. The firm’s market capitalization is $190.23 million.

Athersys (NASDAQ:ATHX) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The firm had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $0.96 million. During the same period in the previous year, the company posted ($0.08) EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, analysts expect that Athersys will post ($0.24) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at

In other Athersys news, EVP John J. Harrington sold 36,000 shares of Athersys stock in a transaction on Friday, June 16th. The shares were sold at an average price of $1.45, for a total transaction of $52,200.00. Following the completion of the sale, the executive vice president now owns 712,743 shares of the company’s stock, valued at approximately $1,033,477.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 9.40% of the company’s stock.

Several large investors have recently modified their holdings of the stock. TFS Capital LLC bought a new stake in shares of Athersys during the first quarter worth about $149,000. Wells Fargo & Company MN raised its stake in Athersys by 4.8% in the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,800 shares during the last quarter. Teachers Advisors LLC raised its stake in Athersys by 21.9% in the fourth quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 28,178 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Athersys during the fourth quarter valued at about $617,000. Finally, FNY Partners Fund LP acquired a new stake in Athersys during the first quarter valued at about $206,000. 18.12% of the stock is owned by institutional investors.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply